Pyrovalerone

• IUPAC: (RS ) -1 - ( 4-methylphenyl ) -2 - (1- pyrrolidinyl) pentan- 1-one
• Latin: Pyrovaleronum

• C16H23NO ( pyrovalerone )
• C16H23NO · HCl ( pyrovalerone · hydrochloride)

• 3563-49-3 ( pyrovalerone )
• 1147-62-2 ( pyrovalerone · hydrochloride)

Crystals ( pyrovalerone · hydrochloride)

Psychostimulant

• 245.36 g · mol -1 ( pyrovalerone )
• 281.82 g.mol -1 ( pyrovalerone · hydrochloride)

178 ° C ( pyrovalerone · hydrochloride)

Template: Infobox chemical / molecular formula search available

Pyrovalerone is a drug that belongs to the group of psychostimulants. It was developed in the late 1960s and prescribed in France and some other European countries. Indications were chronic fatigue and lethargy or obesity. Since there had been some cases of abuse and dependence, it was taken off the market. In Germany it is considered to be marketable, but not prescription drugs enabled. Since 1 January 2004, it is one of the banned doping substances.

Side effects are loss of appetite, anxiety, insomnia, tremor, and depression after prolonged use.

The " Expert Committee on drug dependence of the World Health Organization " mentioned in his 25th report ( 1989 ) that is believed pyrovalerone is a potent inhibitor of norepinephrine uptake that after 1978, however, no further data have been published concerning the mechanism of action. In 1975 in France were 200 cases of intravenous misuse of pyrovalerone tablets known by drug addicts, who led in all cases to venous thrombosis.